the prospective controlled phase iii clinical trial tested the therapeutic value of the cis-platinum-adriamycin-cyclophosphamide combination ( cap ) , compared with the combination including cyclophosphamide , methotrexate , 5-fluorouracil , vincristine and prednisolone ( cmfvp ) , in untreated metastatic breast cancer .
C0016360
5-fluorouracil
C0055987
cmfvp